Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10946283 | PMC |
| http://dx.doi.org/10.1002/hem3.55 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Novel Methods to Assess Tumor Burden and Minimal Residual Disease in Genitourinary Cancers.
Eur Urol
December 2024
Department of Cancer Medicine and INSERM U981, Université Paris-Sud, Université Paris-Saclay, Gustave Roussy, Villejuif, France.
Article Synopsis
- Advances in molecular diagnostics are transforming how prostate, renal, and urothelial cancers are assessed, offering more accurate detection methods for disease burden and minimal residual disease (MRD).
- A literature review from 1980-2024 highlights emerging radiographic and molecular tools aimed at improving disease quantification and monitoring through innovative technologies and biomarker-informed trials.
- New developments, like novel radiotracers and molecular detection methods (e.g., circulating tumor DNA), provide insights into disease mechanisms and have the potential to enhance clinical management, although full MRD application is still in progress.
Validation of a Spectral Flow Cytometry Single-Tube Panel for the Clinical Diagnosis and Follow-Up of Children and Adolescents with B-Cell Acute Lymphoblastic Leukemia.
Cells
November 2024
Advanced Therapy Research Unit, Hospital Universitario Niño Jesús, 28009 Madrid, Spain.
The ability of flow cytometry to identify and quantify the presence of cell populations defined by their expression profile of specific markers has made this technique a powerful and routinary tool in clinical diagnostic practice. Specifically in the field of hematological malignancies, flow cytometry allows the identification of the correct type and lineage of each patient's disease and also sensitively quantifies the presence of the disease at precise moments during treatment, that is, levels of measurable residual disease (MRD). The quantification of MRD by flow cytometry has allowed the adaptation of tailored therapies to patients, contributing to the improvement of the results of the different protocols in recent decades.
View Article and Find Full Text PDFMeasurable residual disease testing and allogeneic hematopoietic cell transplantation for AML: adapting Pre-MEASURE to clinical practice.
Bone Marrow Transplant
November 2024
Division of Transplantation and Cell Therapy, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL, USA.
Measurable residual disease (MRD) testing in patients with acute myelogenous leukemia (AML) represents a heterogenous assessment process designed to quantify leukemia-specific biomarkers that are not ascertainable by routine pathologic evaluation. The most common tools used to assess MRD are multiparameter flow cytometry (MPFC), and polymerase chain reaction (PCR) based tools, including quantitative or digital droplet PCR (qPCR, ddPCR), or next-generation sequencing (NGS) technologies. Collectively, MRD assessments have become an important clinical tool in the management of patients with AML.
View Article and Find Full Text PDFModelling post-chemotherapy stem cell dynamics in the bone marrow niche of AML patients.
Sci Rep
October 2024
Institute for Computational Biomedicine-Disease Modeling, RWTH Aachen University, Aachen, Germany.
Acute myeloid leukemia (AML) is a stem cell-driven malignancy of the blood forming (hematopoietic) system. Despite of high dose chemotherapy with toxic side effects, many patients eventually relapse. The "7+3 regimen", which consists of 7 days of cytarabine in combination with daunorubicin during the first 3 days, is a widely used therapy protocol.
View Article and Find Full Text PDFPatient-Specific Myocardial Infarction Risk Thresholds From AI-Enabled Coronary Plaque Analysis.
Circ Cardiovasc Imaging
October 2024
Biomedical Imaging Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA (R.J.J.M., N.M., A.L., A.S., C.P., A.K., P.M., A.R., K.G., A.C.K., D.H., K.K., G.F.T., J.G., H.G., S.C., D.S.B., P.J.S., D.D.).
Article Synopsis
- Coronary computed tomography angiography (CCTA) is used to evaluate cardiovascular risk by quantifying coronary plaque, and deep learning technology helps automate this process.
- A study involving 2803 patients analyzed how age and sex affect coronary plaque volume and its relation to the risk of myocardial infarction, showing that plaque volume increases with age and is typically higher in men.
- Patients with coronary plaque in the ≥75th percentile were found to have a significantly higher risk of myocardial infarction compared to those below the 50th percentile, suggesting that deep learning-based plaque measurements can effectively predict cardiac events.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!